Results 21 to 30 of about 20,176 (178)

A randomized controlled trial of the short-term effect of rosuvastatin on the corrected QT interval

Scientific Reports
Rosuvastatin can block human ether-a-go-go related gene (hERG) currents and prolong the corrected QT (QTc) interval, but this effect has not been confirmed in the population.
Lijun Zhu, Wenjun Shen, Wanying Hu, Haiwang Guan, Yanwei Wang, Conglin Wang, Jing Lin, Li Chen, Qingjun Jiang   +8 more
doaj   +1 more source

Investigation of montelukast effect on rosuvastatin induced late puberty in rats

Journal of Human Reproductive Sciences, 2022
Background: Puberty is a critical process for the development of sexual organs and reproductive ability. It is triggered and regulated by the hormones.
Tamadir Hamid Wadi Aledani, Manal Nasser Al-Hayder, Suha Haitham Mohammed, Rawaa Salim Al-Mayyahi   +3 more
doaj   +1 more source

Photogenerated Oxetanes as a Gateway to Uphill Cyclopropanation

Angewandte Chemie International Edition, EarlyView.
An atom‐economical route to densely functionalized cyclopropanes from furans and photochemically activated aldehydes is enabled by a unique oxetane‐to‐cyclopropane rearrangement. These cyclopropanes can be used to access complex bioactive scaffolds and serve as a platform for asymmetric cyclopropane synthesis.
Tim Köglmeier, Thomas J. Tiefel, Oliver Reiser   +2 more
wiley   +1 more source

Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial

Lipids in Health and Disease
Objective Rosuvastatin plus ezetimibe improves the lipid-lowering effect through different mechanisms of action. This study intended to compare the efficacy and safety of the fixed-dose combination (FDC) of rosuvastatin/ezetimibe vs.
Xianyou Ji, Jinlan Xia, Hong Zhang, Changjie Ren, Guang Ma, Shenwen Fu, Jun Zhang, Ying Chen, Xuebin Han, Jianming Zhang, Zhengxu Fang, Bo Yang, Baisong Yang, Wenjun Huang, Gang Yin, Hong Qi, Hao Gong, Dongfang Wang, Liuyi Hao, Xiufeng Zhao, Zhaohui Pei, Peijian Wang, Xiaodong Li, Ling Lin, De Li, Zhi Li, Lin Zhang, Bo Yin, Ying Cheng, Zhiqing You, Jianlong Sheng, Jie Wu, Ling Chen, Zhongcai Fan, Wang Zhao, Shuiping Zhao   +35 more
doaj   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

Uncovering Coenzyme Q10‐Related Genetic Determinants of Statin‐Associated Muscle Symptoms: Evidence from the UK Biobank and the All of Us Research Program

Clinical Pharmacology &Therapeutics, EarlyView.
Statin‐associated muscle symptoms (SAMS) are frequent adverse effects of statin therapy and have been hypothesized to result from impaired coenzyme Q10 (CoQ10) biosynthesis. Although genetic determinants of CoQ10 levels have been reported, genome‐wide association studies (GWASs) conducted specifically in statin users are lacking. Moreover, direct CoQ10
Da Hoon Lee, Yoon‐A Park, Yubin Song, Ji‐Min Han, Kyung Hee Choi, Myeong Gyu Kim, Hye Sun Gwak   +6 more
wiley   +1 more source

Rosuvastatin Ameliorates the Initiation and Progression of Lung Adenocarcinoma via Facilitating PLK1 Inhibition

Frontiers in Bioscience-Landmark
Background: Lung cancer remains a major global public health challenge, with lung adenocarcinoma being the most prevalent histologic subtype.
Jie Yin, Jianjie Zhu, Yinhua Gong, Wenting Wu, Xinyu Zhang, Chang Li, Yang Yang, Yili Chen, Jianjun Li, Lei Gu, Jian-an Huang, Zeyi Liu, Dan Shen, Yuanyuan Zeng   +13 more
doaj   +1 more source

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions

Clinical Pharmacology &Therapeutics, EarlyView.
Coproporphyrin I (CPI) is an established endogenous biomarker for detecting drug–drug interactions (DDIs) involving the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, gene SLCO1B1). While CPI has been extensively studied in healthy volunteers using controlled pre‐ and post‐OATP1B1‐inhibitor sampling, its applicability ...
Leila Potzel, Anina Zumtaugwald, Anna Bollinger, Chiara Jeiziner, Kurt E. Hersberger, Florine Wiss, Markus L. Lampert, Samuel S. Allemann, Henriette E. Meyer zu Schwabedissen, Céline K. Stäuble   +9 more
wiley   +1 more source

A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV‐2 (COVID‐19) DHODH (dihydroorotate dehydrogenase) inhibitor

Pharmacology Research & Perspectives, 2023
A therapeutic agent that targets both viral replication and the hyper‐reactive immune response would offer a highly desirable treatment for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; COVID‐19) management.
Terri L. Morton, Oscar L. Laskin, Diksha Kaushik, Lucy Lee, Jiyuan Ma, Allan Kristensen, Kylie O'Keefe, Lee Golden, Matthew Klein, Ronald Kong   +9 more
doaj   +1 more source

The Effect of Rosuvastatin on the Liver Enzyme of NMRI Mouse

Novelty in Biomedicine, 2022
Background: Rosuvastatin is the newest statin family drug and acts as an HMG-CoA reductase inhibitor. Rosuvastatin can decrease the amount of cholesterol made by the liver and reduce the risk of heart disease.
Atena Nehzati Asl, Azadeh Rasooli, Maryam Fazeli, Mehranoush Saffarpour   +3 more
doaj   +1 more source